Tomas Navratil Sells 3,416 Shares of Glaukos Co. (NYSE:GKOS) Stock

Glaukos Co. (NYSE:GKOS) insider Tomas Navratil sold 3,416 shares of the company’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the sale, the insider now owns 72,437 shares of the company’s stock, valued at approximately $10,658,380.18. The trade was a 4.50 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Glaukos Price Performance

Shares of Glaukos stock opened at $157.97 on Friday. Glaukos Co. has a 12 month low of $83.90 and a 12 month high of $163.71. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The stock has a 50 day moving average of $153.00 and a 200 day moving average of $139.16. The firm has a market cap of $8.71 billion, a PE ratio of -52.31 and a beta of 1.04.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. On average, research analysts expect that Glaukos Co. will post -1.89 EPS for the current fiscal year.

Institutional Investors Weigh In On Glaukos

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GKOS. Values First Advisors Inc. purchased a new stake in Glaukos during the third quarter valued at approximately $25,000. IFP Advisors Inc purchased a new stake in shares of Glaukos in the fourth quarter worth approximately $43,000. Asset Planning Inc purchased a new stake in shares of Glaukos in the fourth quarter worth approximately $90,000. CoreCap Advisors LLC raised its holdings in shares of Glaukos by 36.4% in the fourth quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier’s stock worth $112,000 after buying an additional 200 shares during the period. Finally, Harvest Fund Management Co. Ltd raised its holdings in shares of Glaukos by 2,263.2% in the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after buying an additional 860 shares during the period. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on GKOS shares. Stephens raised Glaukos to a “strong-buy” rating in a research note on Monday, December 2nd. BTIG Research upped their price objective on Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Stifel Nicolaus upped their price objective on Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a research note on Tuesday, December 31st. UBS Group started coverage on Glaukos in a research note on Friday, December 6th. They issued a “buy” rating and a $182.00 price objective for the company. Finally, JPMorgan Chase & Co. upped their price objective on Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. One analyst has rated the stock with a sell rating, one has given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $159.42.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.